drugset / Trial / NCT05116930

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

NCT05116930

Phase 2 Recruiting 18 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.

Timeline

Start
2021-11-19
Primary completion
2027-12
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 4 ug/kg Intravenous
Subject Neostigmine Other / unclassified 20 ug/kg Intravenous